Our mission, since 2018, is to advance Leukemia medical research using the latest Internet of Things and Artificial Intelligence technologies, including early detection and drug discovery. We aim to ensure our research, findings, and technologies remain free to anyone that can benefit from their use, whether personal, educational or commercial, providing they contribute back to the community.
Our primary AI drug discovery strategy continues to be focused on the use of GANs (Generative Adversarial Networks) for computational discovery of new bioactive molecules.
We develop open and free Artificial Neural Networks for Natural Language Support Agents to assist Acute Myeloid / Lymphoblastic Leukemia patients, families and friends of leukemia sufferers.
The Peter Moss AML/ALL AI Student Program provides college & university students with real world projects & experience in working with AI for medical purposes, helping further their education and understanding.
Our students communicate with our professors, remotely and in person, and are actively involved in reproducing the results published by various researchers, and developing new models and algorithms for the same. As our student program is an online initiative, Research Interns can participate from anywhere in the world.
Currently there are 3 active students and around 12 students awaiting to start. The program is still very new and we are in the process of planning everything out. We are not accepting new applications at this stage.
Our goal is to advance Leukemia medical research using the latest Internet of Things and Artificial Intelligence technologies. Our team is a group of volunteers with experience in Internet of Things, Computer Vision / Natural Language Processing, Leukemia Research, Biochemistry, Molecular Biophysics, Immunology and Bioinformation. If you would like to join our team as a professional volunteer, please fill out our Professional Volunteer Application.
The Peter Moss Acute Myeloid & Lymphoblastic Leukemia AI Research Project is where everything began in 2018. The research project is an open source initiative with the goals of leveraging Artificial Intelligence to help detect AML/ALL, discover potential candidates for drugs to help combat the diseases, and provide conversational support agents.
The Covid-19 AI Research Project is a Peter Moss Leukemia AI Research research project with the goal of creating open source Robotics, Artificial Intelligence and Internet of Things technologies to assist in the fight against the SARS-CoV-2 (COVID-19) pandemic.
Since our first research project began, we have been dedicated to finding sharing open information with our community. The Leukemia AI Research Information Database is a collection of open information related to Leukemia, other bone marrow cancers and blood diseases.
The Leukemia AI Research Events area is where you will find profiles for events we have organised, spoke at, or visited. The profiles provide information, photos, videos and links for events related to medical technologies, particularly artificial intelligence for medical use.
We are a group of volunteers dedicated to the fight against Leukemia with technology. We have experience in IoT, computer vision / natural language processing, Leukemia research, biochemistry, molecular biophysics, immunology and bioinformation.
Since 2018 we have been volunteering our spare time to researching into how artificial intelligence can be used for early detection of leukemia, drug discovery, and conversational support agents.
The Peter Moss Acute Myeloid/Lymphoblastic Leukemia Detection System is a featured project on Intel Devmesh, the Intel Developer Zone social network.
The project is an open source extension of the GeniSys AI Artificial Intelligence Network that allows you to upload AML/ALL test data and run classifications to detect positive and negative examples using Intel technologies.
The project has recently been voted 1st in Europe out of 4 projects, and awarded the Intel® DevMesh AI Spotlight Award which is a new designation granted by Intel recognizing inspiring and breakthrough Artificial Intelligence projects in development from the Intel software community.